Veerle Van Eygen

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model”.

Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model

New England Journal of Medicine(2025)10.1056/nejmoa2500179

N/A

0.554DataRank · unranked

12 citations

Liesbeth Van Wesenbeeck, Kristen K. Pierce, Guillermo Herrera‐Taracena, Laura Ebone, Annemie Buelens +22 more

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2025)10.1016/s2352-3018(24)00344-8

N/A

0.535DataRank · unranked

12 citations

Kristin Baltrusaitis, Brookie M. Best, Jack Moye, Ellen Townley, Avy Violari +36 more

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Clinical Infectious Diseases(2023)10.1093/cid/ciad020

N/A

0DataRank · unranked

128 citations

Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre‐Marie Girard, Alexander Wong +20 more